Pilot Study on Traditional Chinese Medicine and Food Allergy
NCT ID: NCT02490813
Last Updated: 2023-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
18 participants
INTERVENTIONAL
2015-06-18
2023-02-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In the present study, the investigators would like to examine whether there is reduction in allergic symptoms in food challenge after administering the CHFX for 8 weeks. There will be pre- and post- CHFX food challenges and other related tests.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Controlled Trial of Chinese Herbal Medicine to Treat Allergic Rhinitis
NCT02027194
Dietary Treatment for Chronic Urticaria
NCT02047136
Study on the Mechanism of ZhenQiFuZheng in the Treatment of Allergic Rhinitis Based on Intestinal Flora and Metabolites
NCT06427577
The Effects of Using Yupingfeng Powder with Variation for the Treatment of Allergic Rhinitis
NCT04976023
Study of Yupingfeng Powder Treating Allergic Rhinitis (AR)
NCT06608017
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After determining the baseline tolerance level, subjects in the treatment group will take 2 grams of the CHFX or placebo daily for 8 weeks (week 4 to week 11). The placebo powder consists of food grade medicinal starch blended with coloring agent. After the 8 weeks of treatment, skin prick tests, blood tests as at baseline and oral challenges will be repeated (week 12). During the study subjects will be requested to consume their normal diet but avoiding fish and shellfish, with no consumption of any other Chinese herbal medication. They can take anti-allergic medicines as necessary but will note when medicines are taken in their symptom and peak flow diary.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
This arm will receive the placebo.
Placebo
Placebo will be starch with colorings
Treatment - Chinese Herbal Formula - X
This arm will receive the Chinese Herbal Formula - CHFX as treatment to their existing fish, shrimp or crab allergy.
Treatment - Chinese Herbal Formula - X
Wu Mei (Fructus Pruni Mume), Ling Zhi (Gonoderma), Huang Bai (Cortex Phellodendron), and Zhi Su (Perilla frutescens).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Treatment - Chinese Herbal Formula - X
Wu Mei (Fructus Pruni Mume), Ling Zhi (Gonoderma), Huang Bai (Cortex Phellodendron), and Zhi Su (Perilla frutescens).
Placebo
Placebo will be starch with colorings
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having a positive skin prick test to the cod, shrimp or crab as defined by a weal diameter 3 mm greater than the diluent control.
* Having a positive oral challenge with freeze-dried cod, shrimp or crab.
* Asthma must be under control with a FEV1 of at least 80% predicted value.
* Aspirin, anti-histamines/anti-allergic medicines and antidepressants are not permitted for 3 days, one week and two weeks, respectively, before skin testing or oral food challenge.
Exclusion Criteria
* Requiring systemic glucocorticoids, beta-blockers and ACE inhibitors.
* Having poorly controlled asthma, poorly controlled atopic dermatitis prior to study.
* Inability to discontinue antihistamines or other medication for skin testing and oral challenges.
* Unable to comply with the study protocol for any reason.
8 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Hong Kong Sanatorium & Hospital
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
June Chan, Master
Role: PRINCIPAL_INVESTIGATOR
Hong Kong Sanatorium & Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hong Kong Sanatorium & Hospital
Happy Valley, , Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALC-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.